Literature DB >> 25870146

Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.

Nuala McCabe1, Conor Hanna2, Steven M Walker1, David Gonda3, Jie Li3, Katarina Wikstrom4, Kienan I Savage2, Karl T Butterworth2, Clark Chen3, D Paul Harkin1, Kevin M Prise5, Richard D Kennedy6.   

Abstract

Ataxia telangiectasia mutated (ATM) is an important signaling molecule in the DNA damage response (DDR). ATM loss of function can produce a synthetic lethal phenotype in combination with tumor-associated mutations in FA/BRCA pathway components. In this study, we took an siRNA screening strategy to identify other tumor suppressors that, when inhibited, similarly sensitized cells to ATM inhibition. In this manner, we determined that PTEN and ATM were synthetically lethal when jointly inhibited. PTEN-deficient cells exhibited elevated levels of reactive oxygen species, increased endogenous DNA damage, and constitutive ATM activation. ATM inhibition caused catastrophic DNA damage, mitotic cell cycle arrest, and apoptosis specifically in PTEN-deficient cells in comparison with wild-type cells. Antioxidants abrogated the increase in DNA damage and ATM activation in PTEN-deficient cells, suggesting a requirement for oxidative DNA damage in the mechanism of cell death. Lastly, the ATM inhibitor KU-60019 was specifically toxic to PTEN mutant cancer cells in tumor xenografts and reversible by reintroduction of wild-type PTEN. Together, our results offer a mechanistic rationale for clinical evaluation of ATM inhibitors in PTEN-deficient tumors. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25870146     DOI: 10.1158/0008-5472.CAN-14-3502

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.

Authors:  Laurence Booth; Jane L Roberts; Andrew Poklepovic; Paul Dent
Journal:  Oncol Signal       Date:  2017-08-16

2.  P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage.

Authors:  Ru-Wei Lin; Cheng-Jung Ho; Hsin-Wen Chen; Yu-Hsuan Pao; Li-En Chen; Min-Chi Yang; Shih-Bo Huang; Shiaw Wang; Chung-Hwan Chen; Chihuei Wang
Journal:  Cell Cycle       Date:  2018-09-22       Impact factor: 4.534

3.  PTEN as a Guardian of the Genome: Pathways and Targets.

Authors:  Xinyi Fan; Jeffrey Kraynak; Jonathan P S Knisely; Silvia C Formenti; Wen H Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2020-09-01       Impact factor: 6.915

4.  When the guardian becomes the enemy: Targeting ATM in PTEN-deficient cancers.

Authors:  Nuala McCabe; Steven M Walker; Richard D Kennedy
Journal:  Mol Cell Oncol       Date:  2015-06-10

5.  Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair.

Authors:  Jianhui Ma; Jorge A Benitez; Jie Li; Shunichiro Miki; Claudio Ponte de Albuquerque; Thais Galatro; Laura Orellana; Ciro Zanca; Rachel Reed; Antonia Boyer; Tomoyuki Koga; Nissi M Varki; Tim R Fenton; Suely Kazue Nagahashi Marie; Erik Lindahl; Timothy C Gahman; Andrew K Shiau; Huilin Zhou; John DeGroot; Erik P Sulman; Webster K Cavenee; Richard D Kolodner; Clark C Chen; Frank B Furnari
Journal:  Cancer Cell       Date:  2019-02-28       Impact factor: 31.743

6.  Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection.

Authors:  Mu-Yan Cai; Connor E Dunn; Wenxu Chen; Bose S Kochupurakkal; Huy Nguyen; Lisa A Moreau; Geoffrey I Shapiro; Kalindi Parmar; David Kozono; Alan D D'Andrea
Journal:  Cell Rep       Date:  2020-02-18       Impact factor: 9.423

7.  Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma.

Authors:  Chris W D Armstrong; Jonathan A Coulter; Chee Wee Ong; Pamela J Maxwell; Steven Walker; Karl T Butterworth; Oksana Lyubomska; Silvia Berlingeri; Rebecca Gallagher; Joe M O'Sullivan; Suneil Jain; Ian G Mills; Kevin M Prise; Robert G Bristow; Melissa J LaBonte; David J J Waugh
Journal:  NAR Cancer       Date:  2020-07-03

Review 8.  Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary.

Authors:  Hiroshi Kobayashi; Naoki Kawahara; Kenji Ogawa; Yuki Yamada; Kana Iwai; Emiko Niiro; Sachiko Morioka
Journal:  Biomed Rep       Date:  2018-06-20

Review 9.  Hereditary breast and ovarian cancer: new genes in confined pathways.

Authors:  Finn Cilius Nielsen; Thomas van Overeem Hansen; Claus Storgaard Sørensen
Journal:  Nat Rev Cancer       Date:  2016-08-12       Impact factor: 60.716

10.  Critical DNA damaging pathways in tumorigenesis.

Authors:  Jake A Kloeber; Zhenkun Lou
Journal:  Semin Cancer Biol       Date:  2021-04-24       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.